Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
December 2nd, 2013
Dual-phase cone-beam computed tomography (DP-CBCT) is a useful intraprocedural imaging technique for transarterial chemo-embolization treatment with drug-eluting beads of hepatocellular carcinoma. DP-CBCT has been used to perform three major steps in oncologic interventional radiology: tumor localization (see), navigation and intraprocedural catheter guidance (reach), and intraprocedural evaluation of treatment success (treat).
Overview
Dual-phase cone-beam computed tomography (DP-CBCT) is an advanced imaging technique utilized during transarterial chemo-embolization for hepatocellular carcinoma. This method enhances tumor localization, navigation, and evaluation of treatment success.
Key Study Components
Area of Science
- Interventional Radiology
- Oncology
- Medical Imaging
Background
- Hepatocellular carcinoma is a common liver cancer requiring effective treatment strategies.
- Transarterial chemo-embolization is a minimally invasive procedure for treating liver tumors.
- DP-CBCT provides superior imaging compared to traditional 2D techniques.
- This technique allows for real-time assessment during procedures.
Purpose of Study
- To demonstrate the effectiveness of DP-CBCT in guiding interventional oncology procedures.
- To improve tumor targeting and treatment assessment during chemo-embolization.
- To enhance the overall success rate of liver cancer treatments.
Methods Used
- Patients are positioned supine and sedated for the procedure.
- DP-CBCT scans are performed to visualize the tumor and guide treatment.
- Drug-eluting beads are used for targeted tumor embolization.
- Post-treatment DP-CBCT assesses the effectiveness of the embolization.
Main Results
- DP-CBCT successfully visualizes tumor enhancement and treatment effects.
- Real-time imaging improves navigation and reduces damage to healthy tissue.
- Case studies demonstrate the technique's efficacy in complex tumor locations.
- Enhanced imaging leads to better treatment outcomes in hepatocellular carcinoma.
Conclusions
- DP-CBCT is a valuable tool in interventional oncology for liver cancer.
- The technique improves the precision of tumor targeting and treatment evaluation.
- Future applications may extend to other areas of interventional radiology.
Frequently Asked Questions
Executive Industry Relevance
Dual-phase cone-beam computed tomography (DP-CBCT) enhances precision in interventional oncology by enabling real-time 3D tumor visualization, device navigation, and intraprocedural treatment assessment during transarterial chemo-embolization. This capability supports mechanistic de-risking in hepatocellular carcinoma therapy by improving target confirmation and reducing off-target embolization. The method strengthens translational continuity from preclinical modeling to clinical intervention by providing quantitative, reproducible imaging endpoints.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables functional validation of tumor vasculature and feeding artery identification to support target engagement hypotheses.
- Operational Value: Provides reproducible 3D roadmaps for consistent device navigation across operators and sessions.
- Predictive Value: Facilitates early assessment of embolization efficacy, enabling go/no-go decisions during procedure execution.
Screening & Assay Development
- Scientific Value: Generates quantitative contrast enhancement metrics to evaluate tumor perfusion changes pre- and post-embolization.
- Operational Value: Standardizes intraprocedural imaging acquisition with breath-hold protocols and automatic scan registration.
- Assay Readiness: Produces segmented tumor volumes and vessel maps suitable for automated analysis and cross-platform comparison.
Translational & Preclinical Research
- Translational Continuity: Bridges preclinical imaging models to clinical intervention by replicating multi-phasic assessment in the angio suite.
- Mechanistic De-risking: Reduces uncertainty in drug delivery localization by confirming catheter position relative to tumor-feeding arteries.
- Predictive Confidence: Enables correlation of intraprocedural DP-CBCT findings with post-procedural outcomes to inform dose-response modeling.
Pipeline & Workflow Integration
DP-CBCT integrates into the interventional oncology workflow from tumor localization (See) through catheter navigation (Reach) to embolization confirmation (Treat), supporting seamless transition from target validation to treatment assessment.
- Discovery Biology: Supports hypothesis testing of tumor vascularity and arterial supply through direct 3D visualization of feeding vessels.
- Screening: Enables standardized, reproducible tumor segmentation and contrast dynamics measurement for consistent biomarker evaluation.
- Analytics: Provides quantitative outputs including tumor volume, enhancement patterns, and vascular mapping for comparative analysis.
- Translational Research: Aligns with preclinical imaging biomarkers by delivering comparable multi-phasic tumor assessment in clinical settings.
- Enterprise Reuse: Establishes a reusable imaging platform applicable across tumor types and interventional specialties beyond hepatocellular carcinoma.
Operational & Enterprise Impact
- Scientific Value: Improves target validation confidence through direct visualization of tumor margins and feeding arteries.
- Operational Value: Enhances reproducibility via standardized acquisition protocols and automatic multi-planar registration.
- Strategic Value: Reduces procedural uncertainty and collateral damage, supporting better risk-adjusted resource allocation.
- Portfolio Impact: Enables data-driven advancement decisions based on intraprocedural treatment response metrics.
Implementation Considerations
- Requires expertise in angiographic technique, contrast timing, and breath-hold coordination.
- Dependent on flat-panel detector C-arm systems with dual-phase acquisition and image fusion software.
- Necessitates standardization of scan timing, patient positioning, and contrast injection protocols across operators.
- Involves adaptation considerations for varying tumor sizes, vascular anatomy, and respiratory motion compensation.
- Limited by radiation dose accumulation and contrast load constraints in repeated acquisitions.
Biopharma FAQs
Chapters in this video
0:05
Title
1:38
Locating Tumor
3:19
Intraprocedural Pretreatment Dual Phase Cone-beam Computed Tomography
3:59
Intervention Planning: Tumor Detection, Tumor Segregation, 3D Roadmap
5:01
Reach and Treat the Tumor
6:20
Representative Dual-phase Cone-beam Computed Tomography Results
8:36
Conclusion
